Tricyclo Ring System Having The Hetero Ring As One Of The Cyclos Patents (Class 514/454)
-
Publication number: 20140037723Abstract: A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in the range of 2 mg to 8 mg, in combination with a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone. Methods for treating obesity, conditions associated with obesity, and other indications are also provided, as are compositions and dosage forms containing low doses of phentermine and topiramate, e.g., 3.75 mg phentermine and 23 mg topiramate.Type: ApplicationFiled: October 8, 2013Publication date: February 6, 2014Inventors: Thomas Najarian, Peter Y. Tam, Leland F. Wilson
-
Patent number: 8642645Abstract: The present invention relates to a pharmaceutical composition comprising ?9 Tetrahydrocannabinol (THC), Cannabidiol (CBD), and at least one small molecule selected from Citric Acid, Ascorbic Acid, Citrus Essential Oil(s), Lecithin, one or more sugar(s), Resvertrol, and combinations thereof, wherein the composition exhibits an increased but negated psychoactivity with concurrent enhancement in therapeutic potency of THC and/or CBD. The present invention is further directed to methods of treating one or more disease(s) or disorder(s) modulated by the activation of the Cannabinoid CB1 and/or CB2 receptors, by administering a therapeutically effective amount of the composition of the present invention to a subject in need thereof.Type: GrantFiled: January 30, 2012Date of Patent: February 4, 2014Assignee: Brooks Kelly Research, LLC.Inventor: Brooks J. Kelly
-
Patent number: 8642080Abstract: The invention relates to drug delivery systems comprising a water-soluble polymer matrix and a bioactive agent entrained therein, said water soluble polymer matrix containing at least 50 wt. % of polyoxazoline having a molar mass of at least 5 40,000 g/mol. The drug delivery systems of the present invention offer the advantage that the bioactive agent is readily released when the drug delivery system is contacted with water. The drug delivery system can be in the form of a solid dispersion, a mucoadhesive sheet, a tablet, a powder, a capsule.Type: GrantFiled: June 28, 2010Date of Patent: February 4, 2014Assignee: Bender Analytical Holdong B.V.Inventors: Johannes Caspar Mathias Elizabeth Bender, Richard Hoogenboom, Patrick Andreas Anton van Vliet
-
Publication number: 20140031388Abstract: Anticancer compounds according to formula I are described herein. wherein R1, R2, R3 and R4 are selected from H, CH3, OH, SH, OCH3, NHR?, halogen, CF3, N-linked pyrrolidine, and SO2NHR?, or any combination thereof; R5 is an alkyl, alkenyl, or alkaryl group including from 4 to 11 carbons, X is selected from CH2, CHOH, C?O, S?O, O?S?O, and an oxetane ring, Y is selected from CH2, O, and NH, and R? is a H, aryl, or a lower alkyl group, or pharmaceutically acceptable salts thereof. The compounds have been shown to facilitate site-specific dephosphorylation of Akt at Ser-473, thereby inactivating Akt and decreasing dysregulation of Akt signaling that can occur in cancer cells.Type: ApplicationFiled: July 26, 2013Publication date: January 30, 2014Inventors: Ching-Shih Chen, Dasheng Wang, Samuel K. Kulp
-
Patent number: 8637685Abstract: The invention provides fluorescent schweinfurthin analogs of formula (I) which are useful as probes and for the treatment of cancer and other diseases.Type: GrantFiled: June 25, 2009Date of Patent: January 28, 2014Assignee: University of Iowa Research FoundationInventors: David F. Wiemer, Jeffrey D. Neighbors, Raymond J. Hohl, Craig Kuder
-
Patent number: 8637087Abstract: The present invention relates to non-psychoactive derivatives of tetrahydrocannabinol, which are useful in treating interstitial cystitis and relieving symptoms thereof. The invention uses (6aR,10aR)-?8-tetrahydrocannabinol-11-oic acids (hereinafter referred to as (6aR,10aR)-?8-THC-11-oic acid), as well as pharmaceutical compositions containing the (6aR,10aR)-?8-THC-11-oic acids, for treatment of interstitial cystitis in a mammal. The invention further covers methods of formulating and administering the compounds and pharmaceutical compositions as therapeutic agents in the treatment of interstitial cystitis, with particularly preferred administration routes being oral and via intravesicular instillation.Type: GrantFiled: November 23, 2009Date of Patent: January 28, 2014Assignee: JB Therapeutics Inc.Inventors: Bobby W. Sandage, Jr., Glenn L. Cooper
-
Publication number: 20140018342Abstract: Disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein each of the substituents is given the definition as set forth in the specification and claims. Also disclosed are pharmaceutical compositions containing the compound of Formula (I) and use of the compound in the treatment of neurodegenerative diseases or conditions such as Alzheimer's disease.Type: ApplicationFiled: April 4, 2012Publication date: January 16, 2014Inventors: Wen-Lian Wu, Duane A. Burnett, William J. Greenlee
-
Patent number: 8629177Abstract: Embodiments of the present invention are directed to articles of manufacture and methods of making such articles having utility for the delivery of cannabinoids as a therapeutic. One embodiment of the present invention directed to the article of manufacture comprises a lyophilized particle or sphere having a diameter of about 100 to 500 nanometers having a shell and comprising a biodegradable polymer containing a cannabinoid. A featured cannabinoid is delta-9-tetrahydrocannabinol (delta-9-THC).Type: GrantFiled: August 23, 2011Date of Patent: January 14, 2014Assignee: Aphios CorporationInventors: Trevor Percival Castor, Geoffrey Purdum
-
Patent number: 8628796Abstract: A room temperature stable cannabinoid formulation is disclosed. In preferred embodiments, the cannabinoid formulation is dronabinol in an oil-based carrier contained within a hard gelatin capsule.Type: GrantFiled: December 9, 2005Date of Patent: January 14, 2014Assignee: Insys Therapeutics, Inc.Inventors: S. George Kottayil, Zhongyuan Zhu, Venkat R. Goskonda
-
Publication number: 20140010760Abstract: The present invention provides a composition and method for targeting hypoxic tumor areas for detection or treatment or a treatment adjuvant for cancer. Specifically, a hypoxia targeting moiety is conjugated to a polymeric micelle containing imaging agents, therapeutic agents, or therapeutic adjuvants.Type: ApplicationFiled: March 14, 2013Publication date: January 9, 2014Inventors: Brij P. Giri, Kristina Gregg, Pritam Singh, Dinesh J. Dagli, Anshu Giri
-
Publication number: 20130345299Abstract: A composition comprising a tetrahydrocannabinol compound, a solvent and an acid, wherein the tetrahydrocannabinol compound may be ?8 tetrahydrocannabinol, (?)-?9-trans-tetrahydrocannabinol or a side chain alkyl derivative of either compound, the solvent may be an oil or C1-C4 alcohol (e.g. sesame oil or ethanol), and the acid may be an organic acid or a mineral acid.Type: ApplicationFiled: June 7, 2013Publication date: December 26, 2013Applicant: Johnson Matthey Public Limited CompanyInventors: Ronald Rossi, Lee Jonathan Silverberg, Robert Hogan, Ramesh M. Shah
-
Publication number: 20130338220Abstract: Dosage forms of compounds of formula I, e.g., ajulemic acid, and methods of delivering these compounds and using these compounds to treat or prevent a CB1/CB2 associated disease are disclosed.Type: ApplicationFiled: October 5, 2011Publication date: December 19, 2013Inventors: Mark Tepper, Kollol Pal
-
Publication number: 20130337052Abstract: Administering a therapeutically effective dose of lithium ions mitigates the side effects of a psychoactive substance such as a cannabinoid. The therapeutically effective dose of lithium ions includes greater than 4 milligrams of lithium and less than 170 milligrams of lithium, or includes between 8 and 32 milligrams of lithium ions per milligram of the psychoactive substance. The therapeutically effective dose of lithium ions is administered using lithium carbonate, lithium citrate, lithium chloride, lithium orotate, lithium aspartate, or analogs thereof using a delivery vehicle selected from pills, tablets, capsules, gelcaps, liquids, syrups, injectable liquids, powders, or foods and administered prior to, with, or after administration of the psychoactive substance. The psychoactive substance includes one or more of anandamide, 2-arachidonoyl glycerol, 2-arachidonoyl glycerol ether, tetrahydrocannabinol, cannabinol, cannabidiol, or analogs thereof and may be administered using the delivery vehicle.Type: ApplicationFiled: September 24, 2012Publication date: December 19, 2013Inventors: Patricia Linert, Kenneth J. Ouimet
-
Publication number: 20130323310Abstract: Swellable particles for delivering a working agent to the pulmonary system comprise a plurality of biodegradable particles each formed from a polymer network, each of the plurality of biodegradable particles having a mass mean aerodynamic diameter not exceeding 5 ?m, the particles being swellable by hydration to a size that is greater than 6 ?m volume mean diameter, and a working agent entrapped in the polymer network of each of the plurality of biodegradable particles.Type: ApplicationFiled: April 19, 2013Publication date: December 5, 2013Applicant: STC.UNMInventors: Hugh D. Smyth, Martin J. Donovan
-
Patent number: 8586767Abstract: This invention discloses cannabinoid derivatives and pharmaceutical uses thereof.Type: GrantFiled: January 23, 2012Date of Patent: November 19, 2013Inventor: Craig Rick Travis
-
Publication number: 20130302422Abstract: Provided is a pharmaceutical composition for the treatment and prevention of kidney diseases, containing (a) a therapeutically effective amount of a compound represented by Formulae 1 or 2 or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and (b) a pharmaceutically acceptable carrier, diluent or excipient or any combination thereof.Type: ApplicationFiled: May 22, 2013Publication date: November 14, 2013Applicants: KT & G CORPORATION, MAZENCE INC.Inventors: Taehwan Kwak, Myung-Gyu Park, Kyoung Hoon Jung
-
Publication number: 20130303550Abstract: Compounds of formula (IIc); wherein X3 and X4 independently from each other are N or CR8 wherein R8 may be same or different; Y1, Y2, Y3 and Y4 independently from each other are N or CR9 wherein R9 may be same or different and wherein up to 3 of the group Y1, Y2, Y3 and Y4 may be N; their solvates, hydrates, and pharmaceutically acceptable salts, their use for modulating the Wnt signalling pathway activity and their use as a medicament, preferably for the treatment of cancer.Type: ApplicationFiled: November 11, 2011Publication date: November 14, 2013Applicants: Ruprecht-Karls-Universitat Heidelberg, Deutsches KrebsforschungszentrumInventors: Michael Boutros, Rajendra-Prasad Maskey, Corinna Koch, Florian Fuchs, Sandra Steinbrink, Daniel Gilbert
-
Publication number: 20130295026Abstract: The present invention provides a novel composition comprising Nabilone and randomly methylated B-cyclodextrin (RAMEB), wherein the weight ratio (dry weight to dry weight) between Nabilone and RAMEB is about 1:60-1:140. The present invention further provides methods for increasing the bioavailability of Nabilone.Type: ApplicationFiled: November 24, 2011Publication date: November 7, 2013Applicant: AOP Orphan Pharmaceuticals AGInventors: Helmut Viernstein, Stefan Toegel, Regina Schueller
-
Publication number: 20130296344Abstract: Compounds according to the general formula (I) wherein X1, X2, X3 and X4 independently from each other are N or CR8 wherein R8 may be same or different, and wherein up to 3 of the group X1, X2, X3 and X4 may be N; A is a 5- or 6-membered aromatic or heteroaromtic cycle containing 1 to 3 heteroatoms selected from the group consisting of N, O and S wherein A may be substituted by 1 to 5 substituents R which may be same or different; their solvates, hydrates, and pharmaceutically acceptable salts for the treatment of a disorder or disease associated with an aberrant activation of Wnt signalling in a mammal selected from a cell proliferative disorder, rheumatoid arthritis, increased bone density, aging or age-related disorders and/or diseases or Dupuytren disease (superficial fibromatosis).Type: ApplicationFiled: November 11, 2011Publication date: November 7, 2013Applicants: Ruprecht-Karls-Universitat Heidelberg, Deutsches KrebsforschungszentrumInventors: Michael Boutros, Rajendra-Prasad Maskey, Corinna Koch, Florian Fuchs, Sandra Steinbrink, Daniel Gilbert
-
Publication number: 20130296415Abstract: The invention provides a method of manufacturing and packaging a room temperature stable cannabinoid dosage in an oil-based carrier, wherein the method employs the use of blister packaging and an inert gas atmosphere during blister packaging. The invention also provides a room temperature stable cannabinoid dosage prepared by the methods of the invention.Type: ApplicationFiled: March 20, 2013Publication date: November 7, 2013Applicant: Insys Therapeutics, Inc.Inventors: Venkat Goskonda, Ashok Chavan, Kiran Amancha, Scott Crisman, Crystal Lopez
-
Publication number: 20130289102Abstract: The present invention relates to formulations comprising amyris alcohol or an ester of amyris alcohol or combinations thereof to treat acne in humans. These formulations can further comprise a phytoestrogen such as glabridin and miroestrol, an antioxidant such as tetrahydrocurcumin and naturally occurring peroxides such as artemisinin and dihydroartemisinin and combinations thereof for improved effectiveness in treating acne.Type: ApplicationFiled: December 22, 2011Publication date: October 31, 2013Applicant: Trinity Laboratories, Inc.Inventors: Chandra Ulagaraj Singh, Jagaveerabhadra Rao Nulu
-
Patent number: 8569360Abstract: Derivatives and analogs of inhibitors of receptor tyrosine kinase c-Met obtained by virtual screening, pharmaceutical compositions containing derivatives and analogs of c-Met inhibitors are provided. Methods of making derivatives and analogs of c-Met inhibitors and methods of use thereof are provided.Type: GrantFiled: March 31, 2009Date of Patent: October 29, 2013Inventors: Donald P. Bottaro, Megan Peach, Marc Nicklaus, Nelly Tan
-
Publication number: 20130280343Abstract: A process, wherein food-producing livestock are administered cannabinoid receptor agonists, is used to induce physiological and/or behavioral effects in the livestock. Food products are then derived from the livestock.Type: ApplicationFiled: April 20, 2012Publication date: October 24, 2013Inventor: Justin Lee Roettger
-
Publication number: 20130281523Abstract: The present invention provides methods for treating cannabinoid-sensitive disorders with a lose-dose oral cannabinoid which results in delivery of a therapeutic level during an extended clinically-relevant therapeutic window. These methods provide therapeutic dosing while maintaining safe, side effect sparing, levels of a cannabinoid. The present invention also provides methods of determining optimal dosing in treated patients.Type: ApplicationFiled: November 18, 2011Publication date: October 24, 2013Inventors: Peter Letendre, David Carley
-
Publication number: 20130281913Abstract: The present disclosure provides biophotonic topical compositions and methods useful in phototherapy. In particular, the biophotonic topical compositions of the present disclosure are substantially resistant to leaching such that very low amounts of chromophore(s) present in the biophotonic composition leach out of the composition. The biophotonic compositions and the methods of the present disclosure are useful for promoting wound healing and skin rejuvenation, as well as treating acne and various skin disorders.Type: ApplicationFiled: March 14, 2013Publication date: October 24, 2013Inventor: KLOX Technologies Inc.
-
Publication number: 20130274321Abstract: The present invention provides a method for a topical treatment of a skin cyst. The method includes: applying a formulation to the skin cyst of a mammal; wherein the formulation includes: a dimethyl sulfoxide extract of mature, dried, powdered Cannabis sativa flower and bud leaves, wherein the mature, dried, powdered Cannabis sativa flower and bud leaves include greater than or equal to about 10 weight percent of tetrahydrocannibolinic acid and have been heated for approximately five minutes at a temperature greater than or equal to about 160° C. to less than about 193° C.Type: ApplicationFiled: June 7, 2013Publication date: October 17, 2013Inventor: Jon Newland
-
Publication number: 20130274323Abstract: Disclosed are methods of enhancing the chemotherapeutic treatment of tumor cells, reducing resistance of a cancer cell to a chemotherapeutic agent, a method of inhibiting ABCG2, Pgp, or MRP1 in a mammal afflicted with cancer, and a method of increasing the bioavailability of an ABCG2 substrate drug in a mammal. The methods comprise administering effective amounts of certain compounds to the mammal, for example, a compound of the formula (I): wherein R1, R2, R3, X1, X2, X3, a, and b are as described herein. Uses of these compounds in the preparation of a medicament are also disclosed. Also disclosed are compounds of formula (II), pharmaceutical compositions comprising such compounds and uses thereof.Type: ApplicationFiled: June 5, 2013Publication date: October 17, 2013Inventors: Curtis J. Henrich, Heidi R. Bokesch, Laura K. Cartner, Richard W. Fuller, Kirk R. Gustafson, Kentaro Takada, James B. McMahon, Susan E. Bates, Robert W. Robey, Suneet Shukla, Suresh V. Ambudkar, Michael C. Dean
-
Publication number: 20130274322Abstract: A new process for the manufacture of iodinated xanthenes in high purity includes a cyclization step followed by an iodination step. No extraction, chromatographic or solvent concentration steps are required, and the intermediate as well as final compounds are isolated via filtration or similar means. The process requires a single organic solvent, and the steps are completed at temperatures below 100° C. The exclusion of chloride ions, of chloride free-radicals, hypochlorite ions, or hypochlorous acid as reagents or from reagents that may generate these species in situ in the presence of oxidants, prevents undesirable impurity formation. Several new compounds have been conceived and isolated using these methods. These new compounds are also formed into new medicaments.Type: ApplicationFiled: June 12, 2013Publication date: October 17, 2013Inventors: Jamie Singer, Eric A. Wachter, Timothy Scott, Marlon Lutz, Kevin Babiak
-
Publication number: 20130267502Abstract: This disclosure is directed to treatment of addictions and primary impulse-control disorders using phosphodiesterase 7 (PDE7) inhibitors, alone or in combination with other therapeutic agents.Type: ApplicationFiled: March 15, 2013Publication date: October 10, 2013Inventors: Gregory A. Demopulos, George A. Gaitanaris, Roberto Ciccocioppo
-
Patent number: 8552057Abstract: Select phytoestrogen pharmaceutical compositions and methods of use for promoting neurological heath and prevention of age-related neurodegeneration, such as AD, have been developed. These select phytoestrogen formulations are composed of a number of plant-derived estrogenic molecules and/or their structural analogues and exhibit binding preference to ER? over ER? and agonist activity in the brain. These ER?-selective phytoestrogen formulations cross the blood-brain-barrier and promote estrogen-associated neurotrophism and neuroprotections mechanisms in the brain, without activating proliferative mechanisms in the reproductive tissues and are therefore devoid of other estrogen-associated problematic aspects.Type: GrantFiled: January 31, 2012Date of Patent: October 8, 2013Assignee: University of Southern CaliforniaInventors: Roberta Diaz Brinton, Liqin Zhao
-
Patent number: 8546342Abstract: A composition of three compounds each selected from a selective re-uptake inhibitor of serotonin, a monoamine oxidase inhibitor, and a phosphodiesterase inhibitor, such that all three compounds are different and are naturally occurring.Type: GrantFiled: March 1, 2012Date of Patent: October 1, 2013Inventor: Thomas Christian Lines
-
Publication number: 20130253046Abstract: Disclosed herein are methods for determining whether an individual with cancer is suitable for a treatment with an NQO1 bioactivatable drug, predicting responsiveness of an individual with cancer to a treatment with an NQO1 bioactivatable drug, and treating an individual with cancer with an NQO1 bioactivatable drug composition.Type: ApplicationFiled: September 22, 2011Publication date: September 26, 2013Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventor: David BOOTHMAN
-
Publication number: 20130245111Abstract: Provided is a pharmaceutical composition for the treatment and prevention of obesity, diabetes, metabolic syndromes, degenerative diseases and mitochondrial dysfunction-related diseases, comprising: a therapeutically effective amount of a compound represented by Formula I below, or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof. wherein R1 through R8 and n are as defined in this disclosure.Type: ApplicationFiled: April 25, 2013Publication date: September 19, 2013Applicants: KT & G CO., LTD., MD BIOALPHA CO., LTD.Inventors: Sang-Ku YOO, Myunggyu PARK, In Geun JO, Taehwan KWAK
-
Publication number: 20130245110Abstract: The present invention relates to the use of CBD alone or in combination with another cannabinoid, in the manufacture of a pharmaceutical or neutraceutical formulation for use in controlling cholesterol levels in a subject. It also relates to the use of THCV alone or in combination with another cannabinoid, in the manufacture of a pharmaceutical or neutraceutical formulation for use in increasing energy expenditure in a subject. Furthermore the CBD alone or in combination with another cannabinoid or the THCV alone or in combination with another cannabinoid are used as part of a regime to manage or treat type I or II diabetes, obesity, dyslipidaemia, related metabolic disorders and cardiovascular disease.Type: ApplicationFiled: January 7, 2013Publication date: September 19, 2013Applicant: GW Pharma LimitedInventors: Geoffrey Guy, Stephen Wright, Michael Anthony Cawthorne, Saoirse O'Sullivan
-
Publication number: 20130245109Abstract: The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt/wt of the formulation and the formulation is absent of a self emulsifying agent and/or a fluorinated propellant.Type: ApplicationFiled: June 1, 2012Publication date: September 19, 2013Applicant: GW Pharma LimitedInventor: Brian Anthony Whittle
-
Publication number: 20130231385Abstract: The present invention includes bis- and tris-benzamide compounds that block AR signaling and have anticancer activity. Uses for these compounds, and pharmaceutical compositions containing the same, also are provided.Type: ApplicationFiled: May 27, 2011Publication date: September 5, 2013Applicant: The Board of Regents of the University of Texas SystemsInventors: Jung-Mo Ahn, Ganesh Raj
-
Publication number: 20130209483Abstract: The disclosure relates to cannabinoid derivative compounds, pharmaceutical compositions made thereof, and methods for treating various diseases and disorders including cancer.Type: ApplicationFiled: November 30, 2012Publication date: August 15, 2013Applicant: SUTTER WEST BAY HOSPITALSInventor: SUTTER WEST BAY HOSPITALS
-
Publication number: 20130203843Abstract: The present invention relates to biology and medicine and in particular can be used in medicine for the preparation of a pharmaceutical composition for the specific, self-regulating uncoupling of mitochondria. The invention can be useful in the treatment of diseases and conditions associated with the disruption of cellular metabolism, in the treatment of obesity, including pathological forms thereof, and also for the treatment of diseases associated with the increased formation of free radicals and reactive oxygen species.Type: ApplicationFiled: June 24, 2010Publication date: August 8, 2013Applicant: LIMITED LIABILITY COMPANY MITOTECHInventors: Vladimir Petrovich Skulachev, Maxim Vladimirovich Skulachev, Roman Alexeevich Zinovkin, Fedor Fedorovich Severin, Yury Nikolaevich Antonenko, Dmitry Borisovich Zorov, Egor Yurievich Plotnikov, Nikolay Konstantinovich Isaev, Denis Nikolaevich Silachev, Dmitry Alexeevich Knorre
-
Patent number: 8497299Abstract: The present invention relates to cannabinoic quinone compounds, and especially to their medical use. In particular five cannabinoic quinones, designated HU-331, HU-336, HU-345, HU-395 and HU-396, are described as active agents in pharmaceutical compositions. These compounds and compositions thereof are intended for the treatment of inflammatory, infectious, auto-immune and particularly hyperproliferative disorders. Thus, the compounds of the invention may be used as anti-tumor agents, or for the treatment of cancer. Furthermore, three of these compounds, HU-345, HU-395 and HU-396, are novel cannabinoic quinones.Type: GrantFiled: January 14, 2005Date of Patent: July 30, 2013Assignee: Yissum Research Development Company of The Hebrew University of JerusalemInventors: Raphael Mechoulam, Natalya M. Kogan, Ruth Rabinowitz, Michael Schlesinger
-
Publication number: 20130183388Abstract: Novel indoleamine 2,3-dioxygenase (IDO) inhibitors, compositions comprising the same, and methods of use thereof are disclosed.Type: ApplicationFiled: February 26, 2013Publication date: July 18, 2013Applicant: LANKENAU INSTITUTE FOR MEDICAL RESEARCHInventor: Lankenau Institute for Medical Research
-
Publication number: 20130171259Abstract: Methods for making trans-(?)-?9-tetrahydrocannabinol and trans-(+)-?9-tetrahydrocannabinol are disclosed herein. In one embodiment, a trans-(?)-?9-tetrahydrocannabinol composition is prepared by allowing a composition comprising (±)-?9)-tetrahydrocannabinol to separate on a chiral stationary phase to provide a trans-(?)-?9-tetrahydrocannabinol composition comprising at least about 99% by weight of trans-(?)-?9-tetrahydrocannabinol based on the total amount of trans-(?)-?9-tetrahydrocannabinol and trans-(+)-?9-tetrahydrocannabinol. The invention also relates to methods for treating or preventing a condition such as pain comprising administering to a patient in need thereof an effective amount of a trans-(?)-?9-tetrahydrocannabinol having a purity of at least about 98% based on the total weight of cannabinoids.Type: ApplicationFiled: February 22, 2013Publication date: July 4, 2013Applicant: Purdue Pharma L.P.Inventor: Purdue Pharma L.P.
-
Patent number: 8476312Abstract: A composition comprising a tetrahydrocannabinol compound, a solvent and an acid, wherein the tetrahydrocannabinol compound may be ?8 tetrahydrocannabinol, (?)-?9-trans-tetrahydrocannabinol or a side chain alkyl derivative of either compound, the solvent may be an oil or C1-C4 alcohol (e.g. sesame oil or ethanol), and the acid may be an organic acid or a mineral acid.Type: GrantFiled: August 28, 2012Date of Patent: July 2, 2013Assignee: Johnson Matthey Public Limited CompanyInventors: Ronald Rossi, Lee Jonathan Silverberg, Robert Hogan, Ramesh M. Shah
-
Patent number: 8475776Abstract: Described herein are compositions and methods for preventing and/or treating diseases involving aberrant angiogenesis employing one or more benzo[c]chromen-6-one derivatives.Type: GrantFiled: February 28, 2007Date of Patent: July 2, 2013Assignee: Paloma Pharmaceuticals, Inc.Inventor: David I. Sherris
-
Patent number: 8476307Abstract: A pharmaceutical composition comprising idazoxan or derivatives and their therapeutically acceptable salts, racemates, optically active isomers and polymorphs.Type: GrantFiled: April 15, 2008Date of Patent: July 2, 2013Assignee: Pierre Fabre MedicamentInventors: Joel Bougaret, Jean-Louis Avan, Roland Segonds
-
Publication number: 20130158094Abstract: Tricylic ether carbamates that inhibit HIV proteolytic enzymes and processes for preparing the compounds are describes. Methods of using the disclosed compounds for treating patients infected with HIV are also described.Type: ApplicationFiled: September 2, 2011Publication date: June 20, 2013Applicant: PURDUE RESEARCH FOUNDATIONInventors: Arun K. Ghosh, Chun-Xiao Xu, Hiroaki Mitsuya, Garth Parham
-
Patent number: 8466309Abstract: The disclosure relates to novel compounds of the formula (I) R1NH—CH(R2)CH2—S—S—CH2—C(R3)(R4)—CONH—C(R5)(R6)—COOR7, in which R1 is a (acyloxy)alkyl carbamate-C(O)—O—C(R8)(R9)—OC(O)—R10 group; R2 is a hydrocarbon chain, a methylene radical substituted by a heterocycle, R4 is a hydrogen atom and R3 is a phenyl or benzyl radical, a heteroaryl, a methylene group substituted by a heterocycle or R3 and R4 form together a saturated cycle; R5 and R6 are hydrogen, a hydrocarbon chain, a phenyl or benzyl radical or R5 and R6 form together a saturated cycle; R7 is hydrogen, a phenyl or benzyl radical, a group of the formula CR12(R13)C(O)OR14 or OCR12(R13)OC(O)R14 or OCR12(R13)OC(O)OR14. The disclosure also relates to the use of these compounds as a drug, and to a pharmaceutical composition containing said compounds and a pharmaceutically acceptable carrier.Type: GrantFiled: May 13, 2009Date of Patent: June 18, 2013Inventors: Marie-Claude Fournie-Zaluski, Hervé Poras, Bernard Roques
-
Patent number: 8455252Abstract: Disclosed herein are materials and methods for sensitizing multidrug resistant cancer cells that express ABCG2 and related proteins members of a family of ATP-binding transporter superfamily that mediate drug efflux found in some types of multidrug resistant cancer cells. A series of compounds, including (N-(4-chlorophenyl)-2-[(6-{[4,6-di(4-morpholinyl)-1,3,5-tri-azin-2-yl]amino}-1,3-benzothiazol-2-yl)sulfanyl]acetamide), specifically inhibits ABCG2 and can be used to boost the bio-avail-ability of one or more effective cancer killing drugs, making it possible to use certain widely used chemotherapeutic reagent to treat multidrug resistance cancers. Using these compounds in combination with chemotherapeutic drugs that are substrates for ABCG2 and related proteins may also find utility in treating cancer cells that are not currently identified as multi-drug resistant. Additionally, these compounds appear to accelerate the intercellular degradation of ABCG2 and related proteins.Type: GrantFiled: October 24, 2009Date of Patent: June 4, 2013Assignee: Indiana University Research and Technology Corp.Inventors: Jian-Ting Zhang, Jing Qi, Hui Peng, Zizheng Dong
-
Publication number: 20130123235Abstract: The invention provides tricyclic compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.Type: ApplicationFiled: July 21, 2011Publication date: May 16, 2013Inventors: David Clark, Susan Mary Cramp, Hazel Joan Dyke, Thomas David Pallin, Robert Zahler
-
Publication number: 20130116313Abstract: The present invention relates to methods for identifying agents which bind to specific amino acid residues of the protein interaction site of G protein ? protein subunit. Compounds identified in accordance with the assay of the invention and methods for using the compound for modulating at least one activity of a G protein are also provided.Type: ApplicationFiled: September 28, 2012Publication date: May 9, 2013Applicant: University of RochesterInventor: University of Rochester
-
Publication number: 20130109747Abstract: The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt/wt of the formulation and the formulation is absent of a self emulsifying agent and/or a fluorinated propellant.Type: ApplicationFiled: June 1, 2012Publication date: May 2, 2013Applicant: GW Pharma LimitedInventor: Brian Anthony Whittle